Literature DB >> 22373950

2011 guidelines for the diagnosis and treatment of osteoporosis in Greece.

P Makras1, G Vaiopoulos, G P Lyritis.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22373950

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN： 1108-7161            Impact factor:   2.041


× No keyword cloud information.
  16 in total

1.  Cost-effective osteoporosis treatment thresholds in Greece.

Authors:  P Makras; K Athanasakis; N Boubouchairopoulou; S Rizou; A D Anastasilakis; J Kyriopoulos; G P Lyritis
Journal:  Osteoporos Int       Date:  2015-03-05       Impact factor: 4.507

2.  Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece.

Authors:  Maria P Yavropoulou; Polyzois Makras; Kostas Athanasakis; Vasiliki-Kalliopi Bournia; Konstantinos Mathioudakis; Anastasios Tsolakidis; Eva Kassi; Gregory Kaltsas; Panagiota Mitrou; Petros P Sfikakis
Journal:  Arch Osteoporos       Date:  2022-06-28       Impact factor: 2.879

Review 3.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

4.  Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy.

Authors:  Luisella Cianferotti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

5.  Novel algorithm generating strategy to identify high fracture risk population using a hybrid intervention threshold.

Authors:  Chung-Yuan Hsu; Chih-Hsing Wu; Shan-Fu Yu; Yu-Jih Su; Wen-Chan Chiu; Ying-Chou Chen; Han-Ming Lai; Jia-Feng Chen; Chi-Hua Ko; Jung-Fu Chen; Tien-Tsai Cheng
Journal:  J Bone Miner Metab       Date:  2019-10-03       Impact factor: 2.626

Review 6.  Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Authors:  Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

7.  Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.

Authors:  Athanasios D Anastasilakis; Konstantinos A Toulis; Stergios A Polyzos; Chrysostomos D Anastasilakis; Polyzois Makras
Journal:  Ther Clin Risk Manag       Date:  2012-06-19       Impact factor: 2.423

8.  Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.

Authors:  P Hadji; N Papaioannou; E Gielen; M Feudjo Tepie; E Zhang; I Frieling; P Geusens; P Makras; H Resch; G Möller; L Kalouche-Khalil; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2015-05-28       Impact factor: 4.507

9.  Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.

Authors:  A Fahrleitner-Pammer; N Papaioannou; E Gielen; M Feudjo Tepie; C Toffis; I Frieling; P Geusens; P Makras; E Boschitsch; J Callens; A D Anastasilakis; C Niedhart; H Resch; L Kalouche-Khalil; P Hadji
Journal:  Arch Osteoporos       Date:  2017-06-22       Impact factor: 2.617

10.  Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece.

Authors:  P Makras; N Boubouchairopoulou; I Katsarolis; K Athanasakis
Journal:  J Musculoskelet Neuronal Interact       Date:  2017-12-01       Impact factor: 2.041
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.